Skip to main content

Table 1 Participants

From: “It was an important part of my treatment”: a qualitative study of Norwegian breast Cancer patients’ experiences with mainstreamed genetic testing

16 women from the university hospital and 14 women from the regional hospital were invited to participate.

11 women from the university hospital and 11 women from the regional hospital participated.

22/30 (73%)

When genetic testing was offered to the patient and by whom

Participants (n = 22)

By surgeon before surgery

8 (36.4%)

By surgeon after surgery

5 (22.7%)

By oncologist during neo-adjuvant therapy

4 (18.2%)

By oncologist during adjuvant therapy

3 (13.6%)

During radiation treatment

1 (4.5%)

Could not remember

1 (4.5%)

Asked for the test themselves

6 (27.3%)

Time from diagnosis to interview

Range: 2–4 years (mean 3)

Age at diagnosis

Range: 35–64 years (mean 48.7)

Age at interview

Range: 38–66 years (mean 51.6)

Results from genetic test

One positive for a BRCA2 pathogenic variant 21 normal test results